Skip to main content
. Author manuscript; available in PMC: 2022 Feb 28.
Published in final edited form as: Oncogene. 2021 Oct 30;41(2):220–232. doi: 10.1038/s41388-021-02086-9

Fig. 2. Effect of blocking of EGFR and downstream pathways on SNX3 protein levels.

Fig. 2

Western blotting for SNX3, p-EGFR, p-AKT, p-ERK, EGFR, AKT, and ERK in MCF10A cells pre-treated with (A) AG1478 (25 μM) for 12 h, (B) with MK2206 (1 μM), (C) with PD0325901 (1 μM) for 4 h. Pre-treated cells were stimulated with EGF (20 ng/ml) for the indicated time points. Blots are representative of 3 independent experiments. Bars show densitometric quantification of SNX3 levels (mean (SD) of 3 experiments). One-way ANOVA with Tukey’s multiple comparison test was used, *p < 0.05, **p < 0.01, **** indicates p < 0.0001. (D) RT-qPCR for the mRNA levels of SNX3 in MCF10A cells upon EGF stimulation (30 min or 720 min) and inhibitor treatments compared with untreated cells. MYC expression was used as a positive control. The fold change for SNX3 mRNA was calculated as described. The data represent the mean (SD) of 3 independent treatments. One-way ANOVA with Dunnett’s multiple comparison test was used, *p < 0.05, ***p < 0.001, ****p < 0.0001.